SCHEMBL2656909

SCHEMBL2656909

NC(=S)Nc1ncc(C(F)(F)F)cc1Oc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.47
USP2 O75604 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 6/20 0.41
GAA P10253 4/20 0.41
HTT P42858 2/20 0.41
NOD2 Q9HC29 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
GCK P35557 1/20 0.39
LMNA P02545 1/20 0.39
ALOX12 P18054 1/20 0.39
AGTR1 P30556 1/20 0.39
RAB9A P51151 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
SCN8A Q9UQD0 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654831 0.83 KCNH2 (0.52) SMN1; SMN2KMT2AMAPTKDM4EALDH1A1
SCHEMBL1329681 0.81 PLAU (0.56) SMN1; SMN2KMT2AMAPTKDM4EALDH1A1
SCHEMBL1327994 0.81 GCK (0.54) SMN1; SMN2MAPTALDH1A1GCKALOX12
SCHEMBL3603243 0.81 ICAM1 (0.42) SMN1; SMN2MAPTKDM4EALDH1A1GCK
SCHEMBL4515885 0.76 SMN1; SMN2 (0.49) SMN1; SMN2USP2KMT2AMAPTKDM4E
SCHEMBL2661725 0.76 SMN1; SMN2 (0.49) SMN1; SMN2USP2KMT2AMAPTKDM4E
SCHEMBL2658934 0.75 SMN1; SMN2 (0.77) SMN1; SMN2USP2KMT2AMAPTKDM4E
SCHEMBL11159802 0.75 MAPT (0.52) SMN1; SMN2KMT2AMAPTKDM4EALDH1A1
SCHEMBL1328663 0.73 GCK (0.61) GCK
SCHEMBL2780020 0.73 ALDH1A1 (0.62) SMN1; SMN2KMT2AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362037-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2013-01-29 US disclosed
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPPHARMA INC. (US) 2010-04-29 US disclosed
EP-2173745-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2010-04-14 EP disclosed
WO-2008118718-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 SMN1; SMN2 2184/4885USP2 2955/4885KMT2A 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.